, Volume 7, Issue 1, pp 77–80 | Cite as

Effects of age and estrogen status on the skeletal IGF regulatory system

Studies with human marrow
  • Clifford J. Rosen
  • Donald Verault
  • Christopher Steffens
  • Domingo Cheleuitte
  • Julie Glowacki
Symposium on the Assessment of the Growth Hormone/IGF-I Axis in Aging


Human marrow was obtained as material discarded during total hip replacement and was established in culture with phenol red-free α-MEM with 10% fetal bovine serum (FBS) and antibiotics. Insulin-like growth factor I (IGF-I) and its binding proteins were secreted by human marrow cells, in amounts that increased with time in culture. Western ligand blotting showed that insulin-like growth factor binding protein-3 (IGFBP-3) accounted for the majority (∼75%) of the secreted binding proteins. Evidence for marrow secretion of BP-3 protease was found by electrophoretic analysis of mixtures of radiolabeled IGFBP-3 and marrow-conditioned media. The amount of constitutive secretion of IGFBP-3 increased with age of the subject (r=0.97,p=0.0058). A notable exception was marrow from a postmenopausal women on estrogen replacement therapy (ERT) at the time of surgery; her marrow secreted 89.3 ng/mL after 14 d in vitro, only 38% of the IGFBP-3 that was secreted by cultures from two age-matched peers (208.8 and 285.2 ng/mL). This in vivo effect of estrogen was matched by an in vitro experiment in which 10−8 M 17-β estradiol suppressed IGFBP-3 to 60% of the constitutive level. In all cultures of marrow from postmenopausal women, IL-1β suppressed IGFBP-3 secretion to either undetectable levels or levels between 11% and 35% of control. Thus, human bone marrow cultures demonstrate components of the skeletal IGF regulatory system: IGF-I, IGF-binding proteins, and evidence of IGFBP-3 proteolysis. These results provide evidence of regulation by both systemic (age, estrogen status) and cytokine (IL-1β) factors.

Key Words

IGF aging human marrow in vitro 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Jones, J. I. and Clemmons, D. R. (1995).Endocr. Rev. 16, 3–29.PubMedCrossRefGoogle Scholar
  2. 2.
    Rosen, C. J., Donahue, L. R., and Hunter, S. J. (1994).Proc. Soc. Exp. Biol. Med. 206, 83–102.PubMedGoogle Scholar
  3. 3.
    Breier, B. H., Gallagher, B. W., and Gluckman, P. D. (1991).Endocrinology 128, 247–357.Google Scholar
  4. 4.
    Glowacki, J. (1995).Calcif. Tissue Int. 56, S50,51.Google Scholar
  5. 5.
    Cheleuitte, D., Mizuno, S., Reichel, H., and Glowacki, J. (1995).J. Bone. Min. Res. 10, S442.Google Scholar
  6. 6.
    Glowacki, J., Connolly, M., Yeh, J., Sledge, C. B., Goloring, S. R., Girasole, G., Jilka, R., and Manolagas, S. (1994).Orthop. Trans. 18, 406.Google Scholar
  7. 7.
    Cohen-Solal, M. E., Graulet, A. M., Geuris, J., Denne, M. A., Bergot, C., Morieux, C., Sedel, L., Kuntz, D., and DeVerneyoul, M. C. (1995).J. Bone Min. Res. 10, 307–314.CrossRefGoogle Scholar
  8. 8.
    Bismar, H., Diel, I., Ziegler, R., and Pfeilschifter, J. (1995).J. Clin. Endo. Metab. 80, 3351–3355.CrossRefGoogle Scholar
  9. 9.
    Flanagan, A. M., Horton, M. A., Dorey, E. L., Collins, D. A., Evely, R. S., Moslley, J. M., Firkin, F. C., Chambers, T. J., Helfrich, M. H., and Martin, T. J. (1992).Int. J. Exp. Path. 73, 387–401.Google Scholar
  10. 10.
    Cheng, S. L., Yang, J. W., Rifas, L., Zhang, S. F., and Avioli, L. V. (1994).Endocrin. 134, 277–286.CrossRefGoogle Scholar
  11. 11.
    Gartner, S. and Kaplan, H. S. (1980).Proc. Natl. Acad. Sci. USA 77, 4756–4759.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc 1997

Authors and Affiliations

  • Clifford J. Rosen
    • 2
  • Donald Verault
    • 2
  • Christopher Steffens
    • 2
  • Domingo Cheleuitte
    • 1
  • Julie Glowacki
    • 1
  1. 1.Department of Orthopedic SurgeryBrigham and Women’s Hospital and Harvard Medical SchoolBoston
  2. 2.St. Joseph’s HospitalBangor

Personalised recommendations